PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
P18, a member of the INK4 family of cyclin-dependent kinase inhibitors, is a tumor suppressor protein and plays a key cell survival role in a variety of human cancers. Under pathophysiological conditions, the INK4 group proteins participate in novel biological functions associated with neuronal diseases and oxidative stress. Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons, and oxidative stress is important in its pathogenesis. Therefore, we examined the effects of PEP-1-p18 on oxidative stress-induced SH-SY5Y cells and in a PD mouse model. The transduced PEP-1-p18 markedly inhibited 1-methyl-4-phenyl pyridinium-induced SH-SY5Y cell death by inhibiting Bax expression levels and DNA fragmentation. Additionally, PEP-1-p18prevented dopaminergic neuronal cell death in the substantia nigra of a 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced PD mouse model. These results indicate that PEP-1-p18 may be a useful therapeutic agent against various diseases and is a potential tool for treating PD. [BMB Reports 2012; 45(9): 532-537]
Abstract
P18, a member of the INK4 family of cyclin-dependent kinase inhibitors, is a tumor suppressor protein and plays a key cell survival role in a variety of human cancers. Under pathophysiological conditions, the INK4 group proteins participate in novel biological functions associated with neuronal diseases and oxidative stress. Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons, and oxidative stress is important in its pathogenesis. Therefore, we examined the effects of PEP-1-p18 on oxidative stress-induced SH-SY5Y cells and in a PD mouse model. The transduced PEP-1-p18 markedly inhibited 1-methyl-4-phenyl pyridinium-induced SH-SY5Y cell death by inhibiting Bax expression levels and DNA fragmentation. Additionally, PEP-1-p18prevented dopaminergic neuronal cell death in the substantia nigra of a 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced PD mouse model. These results indicate that PEP-1-p18 may be a useful therapeutic agent against various diseases and is a potential tool for treating PD. [BMB Reports 2012; 45(9): 532-537]
참고문헌 (30)
- Dawson, T. M., "Molecular pathways of neurodegeneration in Parkinson’s disease", Science, 302, pp.819~822 (2003)
- Eriksen, J. L., "Molecular pathogenesis of Parkinson disease", Arch. Neurol., 62, pp.353~357 (2005)
- Morales-Garcia, J. A., "Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease", PLoS ONE, 6, pp.e17240~ (2011)
- Dauer, W., "Parkinson’s disease: mechanisms and models", Neuron, 39, pp.889~909 (2003)
- Warner, T. T., "Genetic and environmental factors in the cause of Parkinson’s disease", Ann. Neurol., 53, pp.S16~S25 (2003)
- Eriksen, J. L., "Gene dosage and pathogenesis of Parkinson’s disease", Trends Mol. Med., 11, pp.91~96 (2005)
- Tasaki, Y., "Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase", Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells, 2010, pp.1344, 25~33
- Subbareddy, M., "Cell survival, cell death and cell cycle pathway are interconnected: Implications for cancer therapy", Drug Resist. Updates, 10, pp.13~29 (2007)
- Grant, S., "The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy", Drug Resist. Updates, 6, pp.15~26 (2003)
- Schwartz, G. K., "Targeting the cell cycle: a new approach to cancer therapy", J. Clin. Oncol., 23, pp.9408~9421 (2005)
- Eduardo, T. C., "INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions", IUBMB Life, 59, pp.419~426 (2007)
- Wadia, J. S., "Protein transduction technology", Curr. Opin. Biotechnol., 13, pp.52~56 (2002)
- Morris, M. C., "A peptide carrier for the delivery of biologically active proteins into mammalian cells", Nat. Biotechnol., 19, pp.1173~1176 (2001)
- Eum, W. S., "In vivo protein transduction: Biologically active intact PEP-1-superoxide dismutase fusion protein efficiently pro-tects against ischemic insult", Free Radic. Biol. Med., 37, pp.1656~1669 (2004)
- Choi, H. S., "PEP-1-SOD fusion protein efficiently protects against paraquat-induced doparninergic neuron damage in a Parkinson disease mouse model", FREE RADICAL BIOLOGY AND MEDICINE, 41, pp.1058~1068 (2006), ELSEVIER SCIENCE INC
- Ahn, E. H., "Transduced PEP-1-ribosomal protein S3 (rpS3) ameliorates 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice", TOXICOLOGY, 276, pp.192~197 (2010), ELSEVIER IRELAND LTD
- An, J. J., "Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult", FEBS JOURNAL, 275, pp.1296~1308 (2008), BLACKWELL PUBLISHING
- Kim, M. J., "Protective effects of transduced PEP-1-Frataxin protein on oxidative stress-induced neuronal cell death", JOURNAL OF THE NEUROLOGICAL SCIENCES, 298, pp.64~69 (2010), ELSEVIER SCIENCE BV
- Sun Hwa Lee, "Transduced Tat-Annexin protein suppresses inflammationassociated gene expression in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells", BMB Reports, 44(7), pp.484~489 (2011), 생화학분자생물학회
- Min Jea Shin, "Transduced PEP-1-AMPK inhibits the LPS-induced expression of COX-2 and iNOS in Raw264.7 cells", BMB reports, 43(1), pp.40~45 (2010), 한국생화학분자생물학회
- Egleton, R. D., "Bioavailability and transport of peptides and peptide drugs into the brain", Peptides, 18, pp.1431~1439 (1997)
- Dietz, G. P., "Cell-penetrating peptide technology to delivery chaperones and associated factors in diseases and basic research", Curr. Pharm. Biotechnol., 11, pp.167~174 (2010)
- Kim, S. Y., "SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling", Neuroscience Letters, 413(2), pp.132~136 (2007), Elsevier BV
- Young Cheul Chung, "The role of neuroinflammation on the pathogenesis of Parkinson’s disease", BMB Reports, 43(4), pp.225~232 (2010), 생화학분자생물학회
- Brouckaert, G., "Apoptotic pathways and their regulation, In Apoptotic pathway as target for novel therapies in cancer and other diseases" (2005), Springer Academic Press
- Finkel, E., "The mitochondrian: is it central to apoptosis?", Science, 292, pp.624~626 (2001)
- Maddika, S., "Cancer-selective therapy of the further: apoptin and its mechanism of action", Cancer Biol. Ther., 5, pp.10~19 (2006)
- Deng, X., "Bcl-2 retards G1", S cell cycle transition by regulating intracellular ROS, 2003, pp.102, 3179~3185
- Araki, T., "Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-treated mouse", Eur. J. Pharm. Sci., 12, pp.231~238 (2001)
- Bradford, M. A., "A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding", Anal. Biochem., 72, pp.248~254 (1976)